Home › NDC Lookup › Ingredients › Carboxymethylcellulose Sodium, Glycerin › 00023-3416-30
Refresh Optive Carboxymethylcellulose Sodium, Glycerin 5 mg/mL; 9 mg/mL Solution/ Drops, 30 vials — NDC 00023-3416-30 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Refresh Optive Carboxymethylcellulose Sodium, Glycerin 5 mg/mL; 9 mg/mL Solution/ Drops, 30 vials — NDC 0023-3416-30 (Billing 00023-3416-30)

by Allergan, Inc. · 30 VIAL, SINGLE-USE in 1 CARTON / .4 mL in 1 VIAL, SINGLE-USE

This is a package of 30 vials of Refresh Optive Carboxymethylcellulose Sodium, Glycerin 5 mg/mL; 9 mg/mL Solution/ Drops from Allergan, Inc., marketed since Aug 2008 and currently FDA-listed; retail pharmacies pay about $0.3420 per vial (NADAC). It is the main listing for this product, which comes in 3 package sizes.

NDC 00023-3416-30
🏷️ FDA NDC (as labeled) 0023-3416-30 billing pads the labeler segment with a zero
This package
Contains30 vials Cost per ea$0.3420 NADAC Per package$10.26 / 30 vials Pack sizes3 compare ↓
Also priced by: Medicaid pays $1.39/unit — full pricing hub ↓
Main listing for product 0023-3416 · Also comes in: 5 vials 0023-3416-05 60 vials 0023-3416-60
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0023-3416-30 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
0023 labeler · 3416 product · 30 package
Package marketed since
Aug 22, 2008
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
30 EA per package
Barcode (UPC-A, from the NDC)
3 0023341630 3
Medicaid fills, this package
46,827 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0023-3416-30
Product NDC 0023-3416
11-digit billing NDC 00023341630
NCPDP billing unit EA — each (per item)
RxCUI 1100650
UNII K679OBS311, PDC6A3C0OX
Application # M018
SPL Set ID 37e99aa8-02d6-4efb-a862-90bc7fcd5ca5
Established class (EPC) Non-Standardized Chemical Allergen
Physiologic effect Increased Histamine Release; Cell-mediated Immunity; Increased IgG Production
Chemical class Allergens; Glycerol
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2008-08-22
Route OPHTHALMIC
Dosage form SOLUTION/ DROPS
Substance CARBOXYMETHYLCELLULOSE SODIUM; GLYCERIN

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 86209902122012
GCN Seq No 064505
GCN 14449
HICL code 035927
Ingredient (HICL) Carboxymethylcell/Glycerin/Pf
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6T
Therapeutic class — specific (HIC3) Artificial Tears
AHFS code 52:92.00.00
AHFS class Eent Drugs, Miscellaneous
FDB label name REFRESH OPTIVE SENSITIVE DROPS
FDB brand name Refresh Optive Sensitive
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 064505
  • GCN: 14449
  • GPI-14 (Medi-Span): 86209902122012
  • HICL (First Databank): 035927
  • AHFS class code: 52:92.00.00
  • RxCUI (RxNorm): 1100650
Why two NDCs? The FDA registers this code as 0023-3416-30 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00023-3416-30. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name REFRESH OPTIVE SENSITIVE DROPS Ingredient Carboxymethylcell/Glycerin/Pf
🧪 What is this product?

Refresh Optive is an over-the-counter eye drop solution containing carboxymethylcellulose sodium and glycerin. Both ingredients function as lubricants and are typically used to help soothe and moisten dry eyes. Carboxymethylcellulose sodium is a thickening agent that helps the drops stay on the eye surface longer, while glycerin adds moisture and protective coating. This product is an OTC monograph drug, meaning it follows FDA's standard rules for over-the-counter lubricating eye drops.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.342 $10.26 / 30 vials
Medicaid paysCMS SDUD · 12 mo $1.39 $41.76 / 30 vials
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2025 Jan 2026 Feb 2026 May 2026 $0.342 $0.341
Flat over the last 5 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00023-3416-05 0023-3416-05 5 VIAL, SINGLE-USE in 1 CARTON / .4 mL in 1 VIAL, SINGLE-USE Sample — — 2008-08-22 — Active
00023-3416-30 You're viewing this Main listing 30 VIAL, SINGLE-USE in 1 CARTON / .4 mL in 1 VIAL, SINGLE-USE $0.3420 / ea $10.26 2008-08-22 — Active
00023-3416-60 0023-3416-60 60 VIAL, SINGLE-USE in 1 CARTON / .4 mL in 1 VIAL, SINGLE-USE — — 2008-08-22 — Active

In Medicaid, this is the most-dispensed pack of this product — about 80% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 30 vials — 30 vial, single-use in 1 carton / .4 ml in 1 vial, single-use.
How does this package differ from NDC 00023-3416-05?
Both are Refresh Optive Carboxymethylcellulose Sodium, Glycerin 5 mg/mL; 9 mg/mL Solution/ Drops — the drug itself is identical. This page's package is the 30 vials one, while NDC 00023-3416-05 is the 5 vials package.
What NDC number is used to bill for this package of Refresh Optive Carboxymethylcellulose Sodium, Glycerin 5 mg/mL; 9 mg/mL Solution/ Drops?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Refresh Optive 5 mg/mL; 9 mg/mLthis 00023-3416-30 Allergan, 30 vials $0.342 — Availability likely —
Refresh RELIEVA PF 5 mg/mL; 10 mg/mL 00023-4515-30 Allergan, 30 vials $0.453 — Availability likely +32%
Refresh Tears Pf 5 mg/mL; 9 mg/mL 00023-3110-10 Allergan, 1 bottle $1.254 — Availability likely +267%
Refresh Relieva PF Xtra 5 mg/mL; 9 mg/mL 00023-3782-10 Allergan, 1 bottle $1.254 — Availability likely +267%
Refresh Optive 5 mg/mL; 9 mg/mL 00023-3240-01 Allergan, 2 bottles — — Discontinued —
Refresh Relieva 5 mg/mL; 9 mg/mL 00023-6630-03 Allergan, 1 bottle — — FDA listed —
Refresh Relieva Preservative Free 5 mg/mL; 9 mg/mL 00023-6634-01 Allergan, 1 bottle — — FDA listed —
Equate Lubricant Eye Drops .5 g/100mL; .9 g/100mL 11716-0365-05 Hanlim 1 bottle — — FDA listed —
Medics Choice Fresh and Soothe 5 mg/mL; 9 mg/mL 55651-0200-01 KC 1 bottle — — FDA listed —
Medics Choice Fresh and Soothe 5 mg/mL; 9 mg/mL 73669-0200-01 Unimed 1 bottle — — FDA listed —
Equate Optimal Hydration Lubricant Eye Drops .5 g/100mL; .9 g/100mL 79903-0258-05 Walmart, 1 bottle — — FDA listed —
Equate Lubricant Eye Drops .5 g/100mL; .9 g/100mL 79903-0365-05 Walmart 1 bottle — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2008
On the market since
Aug 2008
📍
2026
Currently FDA-listed
18 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII R57ZHV85D4
    Boric acid is a weak acid derived from boron. In medicines, it typically serves as a buffer to help maintain the product's pH level and may act as a preservative in certain formulations.
  • UNII M4I0D6VV5M
    Calcium chloride is a salt compound that acts as a firming agent and source of calcium ions in medications. It's used in formulations to help maintain tablet structure, improve texture, or serve as a buffering agent.
  • UNII RA96B954X6
    Erythritol is a sugar alcohol derived from fermented fruits or grains. It's used as a sweetener and bulking agent in medicines to improve taste without adding significant calories.
  • UNII 0G389FZZ9M
    Levocarnitine is an amino acid derivative that helps transport fatty acids in cells. In medications, it serves as an active nutritional component rather than a typical inactive binder or filler.
  • UNII 02F3473H9O
    A mineral salt used in medications as a source of magnesium. It helps bind ingredients together, improve texture, and maintain the product's stability during storage.
  • UNII 660YQ98I10
    Potassium chloride is a mineral salt used in medicines as a buffer and to help maintain the proper pH balance and stability of the formulation during storage and use.
  • UNII 91MBZ8H3QO
    Sodium borate is an inorganic salt compound used in medicines as a buffer to help maintain a stable pH level, and sometimes as a mild preservative or cleansing agent in topical formulations.
  • UNII B22547B95K
    A salt derived from citric acid that helps maintain the proper acid-base balance in the medicine. It's used as a buffer to keep the product stable and at the right pH level.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

9 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesBoric acid; calcium chloride dihydrate; erythritol; levocarnitine; magnesium chloride hexahydrate; potassium chloride; purified water; sodium borate decahydrate; and sodium citrate dihydrate.

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAllergan, Inc.
FDA applicationM018 (OTC MONOGRAPH DRUG)
Labeler code00023
First marketedAug 2008
Product typeHuman Otc Drug
Portfolio188 products on file

More NDCs from Allergan, Inc. labeler code 00023

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Stop Use and Ask a Doctor If 📄 Keep Out of Reach of Children 📄 Other Information 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 31 words ▾

Uses For the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun. May be used as a protectant against further irritation.

⏱️ Dosage and Administration 46 words ▾

Directions To open, TWIST AND PULL TAB TO REMOVE. Instill 1 or 2 drops in the affected eye(s) as needed and discard container. *Follow your eye doctor’s instructions if you are using this product after an eye surgery (e.g., LASIK) to relieve eye dryness and discomfort.

⚠️ Warnings 94 words ▾

Warnings For external use only. To avoid contamination, do not touch tip of container to any surface. Do not reuse.

Once opened, discard. Do not touch unit-dose tip to eye . If solution changes color or becomes cloudy , do not use.

Stop use and ask a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

🧪 Active Ingredient 7 words ▾

Active ingredients Carboxymethylcellulose sodium 0.5% Glycerin 0.9%

🧪 Inactive Ingredients 23 words ▾

Inactive ingredients Boric acid; calcium chloride dihydrate; erythritol; levocarnitine; magnesium chloride hexahydrate; potassium chloride; purified water; sodium borate decahydrate; and sodium citrate dihydrate.

🎯 Purpose 5 words ▾

Purpose Eye lubricant Eye lubricant

📄 Stop Use and Ask a Doctor If 33 words ▾

Stop use and ask a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours.

📄 Keep Out of Reach of Children 19 words ▾

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

📄 Other Information 26 words ▾

Other information Use only if single-use container is intact. Use before expiration date marked on container. Store at 59°-77°F (15°-25°C). RETAIN THIS CARTON FOR FUTURE REFERENCE.

📄 Questions or Comments 9 words ▾

Questions or comments? 1.800.678.1605 refresh eyedrops .com v2.0DFL3416 Phone

📄 Package Label / Principal Display Panel 50 words ▾

PRINCIPAL DISPLAY PANEL NDC 0023-3416-30 Preservative-free Refresh Optive ® Lubricant Eye Drops Dual-Action Relief For Dry, Sensitive Eyes 30 Vials 0.01 fl oz (0.4 mL) each Sterile NDC 0023-3416-30 Preservative-free Refresh Optive® Lubricant Eye Drops Dual-Action Relief For Dry, Sensitive Eyes 30 Vials 0.01 fl oz (0.4 mL) each Sterile

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
46.8K
Units reimbursed last 4 qtrs
834.8K
Gross reimbursed last 4 qtrs
$1.16M
Avg / prescription
$24.82
Avg / unit
$1.3920
Latest quarter Q1 2026
12KRx
Medicaid pays / ea
$1.3920
gross reimbursed
vs
NADAC / ea
$0.3420
acquisition cost
=
Spread
+$1.0500
+307% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
98% FFS
Fee-for-service · 45,795 Rx Managed care · 1,032 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 9,538 units · 166 per 100k residents MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 807,302 units · 4,125 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 1,128 units · 26.6 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: 3,245 units · 47.3 per 100k residents IN Ohio: no data reported OH Pennsylvania: 2,616 units · 20.2 per 100k residents PA New Jersey: 444 units · 4.8 per 100k residents NJ Massachusetts: no data reported MA California: 3,456 units · 8.9 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: 1,380 units · 69.8 per 100k residents NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: 294 units · 3.4 per 100k residents VA Maryland: no data reported MD Connecticut: 1,200 units · 33.2 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: 4,236 units · 200 per 100k residents NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
3.44,125
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 4,125 /100k
2 New Mexico 200 /100k
3 Minnesota 166 /100k
4 Nebraska 69.8 /100k
5 Indiana 47.3 /100k
6 Connecticut 33.2 /100k
7 Oregon 26.6 /100k
8 Pennsylvania 20.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
30 vials this page00023-3416-30 46,827 Rx · $1,162,135
60 vials00023-3416-60 11,522 Rx · $291,028
5 vials00023-3416-05 No Medicaid data
Drug total (last 4 qtrs): 58,349 Rx · 1,111,786 units · $1,453,164 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
← 00023-3348-07 · Allergan, 00023-3507-05 · Allergan, →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.